Current Computer-Aided Drug DesignCurrent Computer-Aided Drug DesignCurrent Computer-Aided Drug Design1573-40991875-6697Bentham Science64433310.2174/1573409919666230726142418ChemistryResearch ArticleDiscovery of a Potential Allosteric Site in the SARS-CoV-2 Spike Protein and Targeting Allosteric Inhibitor to Stabilize the RBD Down State using a Computational ApproachLiTonginfo@benthamscience.netYanZhenginfo@benthamscience.netZhouWeiinfo@benthamscience.netLiuQuninfo@benthamscience.netLiuJinfenginfo@benthamscience.netHuaHaibinginfo@benthamscience.netChina Pharmaceutical University,, China Pharmaceutical University, The Affiliated Jiangyin Hospital of Nanjing University of Chinese MedicineSchool of Traditional Chinese Pharmacy, China Pharmaceutical UniversitySchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University0106202420678479707012025Copyright ©; 2024, Bentham Science Publishers2024Bentham Science Publishershttps://rjeid.com/1573-4099/article/view/644333

Background:The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a worldwide public health crisis. At present, the development of effective drugs and/or related therapeutics is still the most urgent and important task for combating the virus. The viral entry and associated infectivity mainly rely on its envelope spike protein to recognize and bind to the host cell receptor angiotensin-converting enzyme 2 (ACE2) through a conformational switch of the spike receptor binding domain (RBD) from inactive to active state. Thus, it is of great significance to design an allosteric inhibitor targeting spike to lock it in the inactive and ACE2-inaccessible state.

Objective:This study aims to discover the potential broad-spectrum allosteric inhibitors capable of binding and stabilizing the diverse spike variants, including the wild type, Delta, and Omicron, in the inactive RBD down state.

Methods:In this work, we first detected a potential allosteric pocket within the SARS-CoV-2 spike protein. Then, we performed large-scale structure-based virtual screening by targeting the putative allosteric pocket to identify allosteric inhibitors that could stabilize the spike inactive state. Molecular dynamics simulations were further carried out to evaluate the effects of compound binding on the stability of spike RBD.

Result:Finally, we identified three potential allosteric inhibitors, CPD3, CPD5, and CPD6, against diverse SARS-CoV-2 variants, including Wild-type, Delta, and Omicron variants. Our simulation results showed that the three compounds could stably bind the predicted allosteric site and effectively stabilize the spike in the inactive state.

Conclusion:The three compounds provide novel chemical structures for rational drug design targeting spike protein, which is expected to greatly assist in the development of new drugs against SARS-CoV-2.

Allosteric siteSARS-CoV-2spike proteinallosteric inhibitorRBD down stateACE2-inaccessible state.Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; Niu, P.; Zhan, F.; Ma, X.; Wang, D.; Xu, W.; Wu, G.; Gao, G.F.; Tan, W. A novel coronavirus from patients with pneumonia in china, 2019. N. Engl. J. Med., 2020, 382(8), 727-733. doi: 10.1056/NEJMoa2001017 PMID: 31978945World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. 2022. Available from: https://covid19.who.int/Rahman, S.; Montero, M.T.V.; Rowe, K.; Kirton, R.; Kunik, F., Jr Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: A review of current evidence. Expert Rev. Clin. Pharmacol., 2021, 14(5), 601-621. doi: 10.1080/17512433.2021.1902303 PMID: 33705239Food and Drug Administration. Coronavirus (COVID-19) ⋅ Drugs. 2022. Available from: https://www.fda.gov/drugs/emergency-preparedness-drugs/coronavirus-covid-19-drugsTang, J.W.; Tambyah, P.A.; Hui, D.S.C. Emergence of a new SARS-CoV-2 variant in the UK. J. Infect., 2021, 82(4), e27-e28. doi: 10.1016/j.jinf.2020.12.024 PMID: 33383088Boehm, E.; Kronig, I.; Neher, R.A.; Eckerle, I.; Vetter, P.; Kaiser, L. Novel SARS-CoV-2 variants: The pandemics within the pandemic. Clin. Microbiol. Infect., 2021, 27(8), 1109-1117. doi: 10.1016/j.cmi.2021.05.022 PMID: 34015535Tang, J.W.; Toovey, O.T.R.; Harvey, K.N.; Hui, D.S.C. Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK. J. Infect., 2021, 82(4), e8-e10. doi: 10.1016/j.jinf.2021.01.007 PMID: 33472093Lopez Bernal, J.; Andrews, N.; Gower, C.; Gallagher, E.; Simmons, R.; Thelwall, S.; Stowe, J.; Tessier, E.; Groves, N.; Dabrera, G.; Myers, R.; Campbell, C.N.J.; Amirthalingam, G.; Edmunds, M.; Zambon, M.; Brown, K.E.; Hopkins, S.; Chand, M.; Ramsay, M. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta). Variant. N. Engl. J. Med., 2021, 385(7), 585-594. doi: 10.1056/NEJMoa2108891 PMID: 34289274Lipsitch, M.; Krammer, F.; Regev-Yochay, G.; Lustig, Y.; Balicer, R.D. SARS-CoV-2 breakthrough infections in vaccinated individuals: Measurement, causes and impact. Nat. Rev. Immunol., 2022, 22(1), 57-65. doi: 10.1038/s41577-021-00662-4 PMID: 34876702Artese, A.; Svicher, V.; Costa, G.; Salpini, R.; Di Maio, V.C.; Alkhatib, M.; Ambrosio, F.A.; Santoro, M.M.; Assaraf, Y.G.; Alcaro, S.; Ceccherini-Silberstein, F. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. Drug Resist. Updat., 2020, 53, 100721. doi: 10.1016/j.drup.2020.100721 PMID: 33132205Gordon, D.E.; Jang, G.M.; Bouhaddou, M.; Xu, J.; Obernier, K.; White, K.M.; O’Meara, M.J.; Rezelj, V.V.; Guo, J.Z.; Swaney, D.L.; Tummino, T.A.; Hüttenhain, R.; Kaake, R.M.; Richards, A.L.; Tutuncuoglu, B.; Foussard, H.; Batra, J.; Haas, K.; Modak, M.; Kim, M.; Haas, P.; Polacco, B.J.; Braberg, H.; Fabius, J.M.; Eckhardt, M.; Soucheray, M.; Bennett, M.J.; Cakir, M.; McGregor, M.J.; Li, Q.; Meyer, B.; Roesch, F.; Vallet, T.; Mac Kain, A.; Miorin, L.; Moreno, E.; Naing, Z.Z.C.; Zhou, Y.; Peng, S.; Shi, Y.; Zhang, Z.; Shen, W.; Kirby, I.T.; Melnyk, J.E.; Chorba, J.S.; Lou, K.; Dai, S.A.; Barrio-Hernandez, I.; Memon, D.; Hernandez-Armenta, C.; Lyu, J.; Mathy, C.J.P.; Perica, T.; Pilla, K.B.; Ganesan, S.J.; Saltzberg, D.J.; Rakesh, R.; Liu, X.; Rosenthal, S.B.; Calviello, L.; Venkataramanan, S.; Liboy-Lugo, J.; Lin, Y.; Huang, X.P.; Liu, Y.; Wankowicz, S.A.; Bohn, M.; Safari, M.; Ugur, F.S.; Koh, C.; Savar, N.S.; Tran, Q.D.; Shengjuler, D.; Fletcher, S.J.; O’Neal, M.C.; Cai, Y.; Chang, J.C.J.; Broadhurst, D.J.; Klippsten, S.; Sharp, P.P.; Wenzell, N.A.; Kuzuoglu-Ozturk, D.; Wang, H.Y.; Trenker, R.; Young, J.M.; Cavero, D.A.; Hiatt, J.; Roth, T.L.; Rathore, U.; Subramanian, A.; Noack, J.; Hubert, M.; Stroud, R.M.; Frankel, A.D.; Rosenberg, O.S.; Verba, K.A.; Agard, D.A.; Ott, M.; Emerman, M.; Jura, N.; von Zastrow, M.; Verdin, E.; Ashworth, A.; Schwartz, O.; d’Enfert, C.; Mukherjee, S.; Jacobson, M.; Malik, H.S.; Fujimori, D.G.; Ideker, T.; Craik, C.S.; Floor, S.N.; Fraser, J.S.; Gross, J.D.; Sali, A.; Roth, B.L.; Ruggero, D.; Taunton, J.; Kortemme, T.; Beltrao, P.; Vignuzzi, M.; García-Sastre, A.; Shokat, K.M.; Shoichet, B.K.; Krogan, N.J. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature, 2020, 583(7816), 459-468. doi: 10.1038/s41586-020-2286-9 PMID: 32353859Jamalipour Soufi, G.; Iravani, S. Potential inhibitors of SARS-CoV-2: Recent advances. J. Drug Target., 2021, 29(4), 349-364. doi: 10.1080/1061186X.2020.1853736 PMID: 33210953Li, Q.; Yi, D.; Lei, X.; Zhao, J.; Zhang, Y.; Cui, X.; Xiao, X.; Jiao, T.; Dong, X.; Zhao, X.; Zeng, H.; Liang, C.; Ren, L.; Guo, F.; Li, X.; Wang, J.; Cen, S. Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase. Acta Pharm. Sin. B, 2021, 11(6), 1555-1567. doi: 10.1016/j.apsb.2021.02.011 PMID: 33614402Maio, N.; Lafont, B.A.P.; Sil, D.; Li, Y.; Bollinger, J.M., Jr; Krebs, C.; Pierson, T.C.; Linehan, W.M.; Rouault, T.A. Fe-S cofactors in the SARS-CoV-2 RNA-dependent RNA polymerase are potential antiviral targets. Science, 2021, 373(6551), 236-241. doi: 10.1126/science.abi5224 PMID: 34083449Xiong, M.; Su, H.; Zhao, W.; Xie, H.; Shao, Q.; Xu, Y. What coronavirus 3C‐like protease tells us: From structure, substrate selectivity, to inhibitor design. Med. Res. Rev., 2021, 41(4), 1965-1998. doi: 10.1002/med.21783 PMID: 33460213Drayman, N.; DeMarco, J.K.; Jones, K.A.; Azizi, S.A.; Froggatt, H.M.; Tan, K.; Maltseva, N.I.; Chen, S.; Nicolaescu, V.; Dvorkin, S.; Furlong, K.; Kathayat, R.S.; Firpo, M.R.; Mastrodomenico, V.; Bruce, E.A.; Schmidt, M.M.; Jedrzejczak, R.; Muñoz-Alía, M.Á.; Schuster, B.; Nair, V.; Han, K.; O’Brien, A.; Tomatsidou, A.; Meyer, B.; Vignuzzi, M.; Missiakas, D.; Botten, J.W.; Brooke, C.B.; Lee, H.; Baker, S.C.; Mounce, B.C.; Heaton, N.S.; Severson, W.E.; Palmer, K.E.; Dickinson, B.C.; Joachimiak, A.; Randall, G.; Tay, S. Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Science, 2021, 373(6557), 931-936. doi: 10.1126/science.abg5827 PMID: 34285133Petushkova, A.I.; Zamyatnin, A.A., Jr Papain-like proteases as coronaviral drug targets: Current inhibitors, opportunities, and limitations. pharmaceuticals, 2020, 13(10), 277. doi: 10.3390/ph13100277 PMID: 32998368Gao, X.; Qin, B.; Chen, P.; Zhu, K.; Hou, P.; Wojdyla, J.A.; Wang, M.; Cui, S. Crystal structure of SARS-CoV-2 papain-like protease. Acta Pharm. Sin. B, 2021, 11(1), 237-245. doi: 10.1016/j.apsb.2020.08.014 PMID: 32895623Huang, Y.; Yang, C.; Xu, X.; Xu, W.; Liu, S. Structural and functional properties of SARS-CoV-2 spike protein: Potential antivirus drug development for COVID-19. Acta Pharmacol. Sin., 2020, 41(9), 1141-1149. doi: 10.1038/s41401-020-0485-4 PMID: 32747721Costa, C.F.S.; Barbosa, A.J.M.; Dias, A.M.G.C.; Roque, A.C.A. Native, engineered and de novo designed ligands targeting the SARS-CoV-2 spike protein. Biotechnol. Adv., 2022, 59, 107986. doi: 10.1016/j.biotechadv.2022.107986 PMID: 35598822Beigel, J.H.; Tomashek, K.M.; Dodd, L.E.; Mehta, A.K.; Zingman, B.S.; Kalil, A.C.; Hohmann, E.; Chu, H.Y.; Luetkemeyer, A.; Kline, S.; Lopez de Castilla, D.; Finberg, R.W.; Dierberg, K.; Tapson, V.; Hsieh, L.; Patterson, T.F.; Paredes, R.; Sweeney, D.A.; Short, W.R.; Touloumi, G.; Lye, D.C.; Ohmagari, N.; Oh, M.; Ruiz-Palacios, G.M.; Benfield, T.; Fätkenheuer, G.; Kortepeter, M.G.; Atmar, R.L.; Creech, C.B.; Lundgren, J.; Babiker, A.G.; Pett, S.; Neaton, J.D.; Burgess, T.H.; Bonnett, T.; Green, M.; Makowski, M.; Osinusi, A.; Nayak, S.; Lane, H.C. Remdesivir for the treatment of Covid-19 - Final report. N. Engl. J. Med., 2020, 383(19), 1813-1826. doi: 10.1056/NEJMoa2007764 PMID: 32445440Mahase, E. Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ, 2021, 375(2713), n2713. doi: 10.1136/bmj.n2713 PMID: 34750163Jayk Bernal, A.; Gomes da Silva, M.M.; Musungaie, D.B.; Kovalchuk, E.; Gonzalez, A.; Delos Reyes, V.; Martín-Quirós, A.; Caraco, Y.; Williams-Diaz, A.; Brown, M.L.; Du, J.; Pedley, A.; Assaid, C.; Strizki, J.; Grobler, J.A.; Shamsuddin, H.H.; Tipping, R.; Wan, H.; Paschke, A.; Butterton, J.R.; Johnson, M.G.; De Anda, C. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N. Engl. J. Med., 2022, 386(6), 509-520. doi: 10.1056/NEJMoa2116044 PMID: 34914868Stevens, L.J.; Pruijssers, A.J.; Lee, H.W.; Gordon, C.J.; Tchesnokov, E.P.; Gribble, J.; George, A.S.; Hughes, T.M.; Lu, X.; Li, J.; Perry, J.K.; Porter, D.P.; Cihlar, T.; Sheahan, T.P.; Baric, R.S.; Götte, M.; Denison, M.R. Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms. Sci. Transl. Med., 2022, 14(656), eabo0718. doi: 10.1126/scitranslmed.abo0718 PMID: 35482820Gandhi, S.; Klein, J.; Robertson, A.J.; Peña-Hernández, M.A.; Lin, M.J.; Roychoudhury, P.; Lu, P.; Fournier, J.; Ferguson, D.; Mohamed Bakhash, S.A.K.; Catherine Muenker, M.; Srivathsan, A.; Wunder, E.A., Jr; Kerantzas, N.; Wang, W.; Lindenbach, B.; Pyle, A.; Wilen, C.B.; Ogbuagu, O.; Greninger, A.L.; Iwasaki, A.; Schulz, W.L.; Ko, A.I. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: A case report. Nat. Commun., 2022, 13(1), 1547. doi: 10.1038/s41467-022-29104-y PMID: 35301314Sakamuru, S.; Huang, R.; Xia, M. Use of Tox21 screening data to evaluate the covid-19 drug candidates for their potential toxic effects and related pathways. Front. Pharmacol., 2022, 13, 935399. doi: 10.3389/fphar.2022.935399 PMID: 35910344Fishbane, S.; Hirsch, J.S.; Nair, V. Special considerations for paxlovid treatment among transplant recipients with SARS-CoV-2 infection. Am. J. Kidney Dis., 2022, 79(4), 480-482. doi: 10.1053/j.ajkd.2022.01.001 PMID: 35032591Wen, W.; Chen, C.; Tang, J.; Wang, C.; Zhou, M.; Cheng, Y.; Zhou, X.; Wu, Q.; Zhang, X.; Feng, Z.; Wang, M.; Mao, Q. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:A meta-analysis. Ann. Med., 2022, 54(1), 516-523. doi: 10.1080/07853890.2022.2034936 PMID: 35118917Jackson, C.B.; Farzan, M.; Chen, B.; Choe, H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol., 2022, 23(1), 3-20. doi: 10.1038/s41580-021-00418-x PMID: 34611326Dai, L.; Gao, G.F. Viral targets for vaccines against COVID-19. Nat. Rev. Immunol., 2021, 21(2), 73-82. doi: 10.1038/s41577-020-00480-0 PMID: 33340022Zhou, T.; Tsybovsky, Y.; Gorman, J.; Rapp, M.; Cerutti, G.; Chuang, G.Y.; Katsamba, P.S.; Sampson, J.M.; Schön, A.; Bimela, J.; Boyington, J.C.; Nazzari, A.; Olia, A.S.; Shi, W.; Sastry, M.; Stephens, T.; Stuckey, J.; Teng, I.T.; Wang, P.; Wang, S.; Zhang, B.; Friesner, R.A.; Ho, D.D.; Mascola, J.R.; Shapiro, L.; Kwong, P.D. Cryo-EM Structures of SARS-CoV-2 spike without and with ACE2 reveal a ph-dependent switch to mediate endosomal positioning of receptor-binding domains. Cell Host Microbe., 2020, 28(6), 867-879.e5. doi: 10.1016/j.chom.2020.11.004 PMID: 33271067Li, T.; Yu, L.; Sun, J.; Liu, J.; He, X. Ionization of D571 Is coupled with sarS-CoV-2 spike Up/Down equilibrium revealing the pH-Dependent allosteric mechanism of receptor-binding domains. J. Phys. Chem. B, 2022, 126(26), 4828-4839. doi: 10.1021/acs.jpcb.2c02365 PMID: 35736566Yi, Y.; Li, J.; Lai, X.; Zhang, M.; Kuang, Y.; Bao, Y.O.; Yu, R.; Hong, W.; Muturi, E.; Xue, H.; Wei, H.; Li, T.; Zhuang, H.; Qiao, X.; Xiang, K.; Yang, H.; Ye, M. Natural triterpenoids from licorice potently inhibit SARS-CoV-2 infection. J. Adv. Res., 2022, 36, 201-210. doi: 10.1016/j.jare.2021.11.012 PMID: 35116174Yang, J.; Wang, W.; Chen, Z.; Lu, S.; Yang, F.; Bi, Z.; Bao, L.; Mo, F.; Li, X.; Huang, Y.; Hong, W.; Yang, Y.; Zhao, Y.; Ye, F.; Lin, S.; Deng, W.; Chen, H.; Lei, H.; Zhang, Z.; Luo, M.; Gao, H.; Zheng, Y.; Gong, Y.; Jiang, X.; Xu, Y.; Lv, Q.; Li, D.; Wang, M.; Li, F.; Wang, S.; Wang, G.; Yu, P.; Qu, Y.; Yang, L.; Deng, H.; Tong, A.; Li, J.; Wang, Z.; Yang, J.; Shen, G.; Zhao, Z.; Li, Y.; Luo, J.; Liu, H.; Yu, W.; Yang, M.; Xu, J.; Wang, J.; Li, H.; Wang, H.; Kuang, D.; Lin, P.; Hu, Z.; Guo, W.; Cheng, W.; He, Y.; Song, X.; Chen, C.; Xue, Z.; Yao, S.; Chen, L.; Ma, X.; Chen, S.; Gou, M.; Huang, W.; Wang, Y.; Fan, C.; Tian, Z.; Shi, M.; Wang, F.S.; Dai, L.; Wu, M.; Li, G.; Wang, G.; Peng, Y.; Qian, Z.; Huang, C.; Lau, J.Y.N.; Yang, Z.; Wei, Y.; Cen, X.; Peng, X.; Qin, C.; Zhang, K.; Lu, G.; Wei, X. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature, 2020, 586(7830), 572-577. doi: 10.1038/s41586-020-2599-8 PMID: 32726802Yu, F.; Xiang, R.; Deng, X.; Wang, L.; Yu, Z.; Tian, S.; Liang, R.; Li, Y.; Ying, T.; Jiang, S. Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. Signal Transduct. Target. Ther., 2020, 5(1), 212. doi: 10.1038/s41392-020-00318-0 PMID: 32963228Mahase, E. Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant. BMJ, 2021, 372(296), n296. doi: 10.1136/bmj.n296 PMID: 33526412Wu, L.; Peng, C.; Yang, Y.; Shi, Y.; Zhou, L.; Xu, Z.; Zhu, W. Exploring the immune evasion of SARS-CoV-2 variant harboring E484K by molecular dynamics simulations. Brief. Bioinform., 2022, 23(1), bbab383. doi: 10.1093/bib/bbab383 PMID: 34553217Helfand, M.; Fiordalisi, C.; Wiedrick, J.; Ramsey, K.L.; Armstrong, C.; Gean, E.; Winchell, K.; Arkhipova-Jenkins, I. Risk for reinfection after SARS-CoV-2: A living, rapid review for american college of physicians practice points on the role of the antibody response in conferring immunity following SARS-CoV-2 infection. Ann. Intern. Med., 2022, 175(4), 547-555. doi: 10.7326/M21-4245 PMID: 35073157Lu, M.; Uchil, P.D.; Li, W.; Zheng, D.; Terry, D.S.; Gorman, J.; Shi, W.; Zhang, B.; Zhou, T.; Ding, S.; Gasser, R.; Prévost, J.; Beaudoin-Bussières, G.; Anand, S.P.; Laumaea, A.; Grover, J.R.; Liu, L.; Ho, D.D.; Mascola, J.R.; Finzi, A.; Kwong, P.D.; Blanchard, S.C.; Mothes, W. Real-time conformational dynamics of SARS-CoV-2 spikes on virus particles. Cell Host Microbe, 2020, 28(6), 880-891.e8. doi: 10.1016/j.chom.2020.11.001 PMID: 33242391Tan, Z.W.; Tee, W.V.; Samsudin, F.; Guarnera, E.; Bond, P.J.; Berezovsky, I.N. Allosteric perspective on the mutability and druggability of the SARS-CoV-2 Spike protein. Structure, 2022, 30(4), 590-607.e4. doi: 10.1016/j.str.2021.12.011 PMID: 35063064Toelzer, C.; Gupta, K.; Yadav, S.K.N.; Borucu, U.; Davidson, A.D.; Kavanagh Williamson, M.; Shoemark, D.K.; Garzoni, F.; Staufer, O.; Milligan, R.; Capin, J.; Mulholland, A.J.; Spatz, J.; Fitzgerald, D.; Berger, I.; Schaffitzel, C. Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein. Science, 2020, 370(6517), 725-730. doi: 10.1126/science.abd3255 PMID: 32958580Tong, L.; Wang, L.; Liao, S.; Xiao, X.; Qu, J.; Wu, C.; Zhu, Y.; Tai, W.; Huang, Y.; Wang, P.; Li, L.; Zhang, R.; Xiang, Y.; Cheng, G. A retinol derivative inhibits SARS-CoV-2 infection by interrupting spike-mediated cellular entry. MBio, 2022, 13(4), e01485-e22. doi: 10.1128/mbio.01485-22 PMID: 35862773Wang, Q.; Wang, L.; Zhang, Y.; Zhang, X.; Zhang, L.; Shang, W.; Bai, F. Probing the allosteric inhibition mechanism of a spike protein using molecular dynamics simulations and active compound identifications. J. Med. Chem., 2022, 65(4), 2827-2835. doi: 10.1021/acs.jmedchem.1c00320 PMID: 34415156Wagner, J.R.; Lee, C.T.; Durrant, J.D.; Malmstrom, R.D.; Feher, V.A.; Amaro, R.E. Emerging computational methods for the rational discovery of allosteric drugs. Chem. Rev., 2016, 116(11), 6370-6390. doi: 10.1021/acs.chemrev.5b00631 PMID: 27074285Di Paola, L.; Hadi-Alijanvand, H.; Song, X.; Hu, G.; Giuliani, A. The discovery of a putative allosteric site in the SARS-CoV-2 spike protein Using an integrated structural/dynamic approach. J. Proteome Res., 2020, 19(11), 4576-4586. doi: 10.1021/acs.jproteome.0c00273 PMID: 32551648Webb, B.; Sali, A. Comparative protein structure modeling using MODELLER. Curr Protoc Bioinformatics., 2017, 54, 5.6.37. doi: 10.1002/cpbi.3 PMID: 27322406Case, D.A.; Cheatham, T.E., III; Darden, T.; Gohlke, H.; Luo, R.; Merz, K.M., Jr; Onufriev, A.; Simmerling, C.; Wang, B.; Woods, R.J. The Amber biomolecular simulation programs. J. Comput. Chem., 2005, 26(16), 1668-1688. doi: 10.1002/jcc.20290 PMID: 16200636Le Guilloux, V.; Schmidtke, P.; Tuffery, P. Fpocket: An open source platform for ligand pocket detection. BMC Bioinformatics, 2009, 10(1), 168. doi: 10.1186/1471-2105-10-168 PMID: 19486540Liang, J.; Woodward, C.; Edelsbrunner, H. Anatomy of protein pockets and cavities: Measurement of binding site geometry and implications for ligand design. Protein Sci., 1998, 7(9), 1884-1897. doi: 10.1002/pro.5560070905 PMID: 9761470Santos-Martins, D.; Solis-Vasquez, L.; Tillack, A.F.; Sanner, M.F.; Koch, A.; Forli, S. Accelerating A UTO D OCK 4 with GPUs and Gradient-Based Local Search. J. Chem. Theory Comput., 2021, 17(2), 1060-1073. doi: 10.1021/acs.jctc.0c01006 PMID: 33403848O’Boyle, N.M.; Banck, M.; James, C.A.; Morley, C.; Vandermeersch, T.; Hutchison, G.R. Open Babel: An open chemical toolbox. J. Cheminform., 2011, 3(1), 33. doi: 10.1186/1758-2946-3-33 PMID: 21982300Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem., 2009, 30(16), 2785-2791. doi: 10.1002/jcc.21256 PMID: 19399780Huey, R.; Morris, G.M.; Olson, A.J.; Goodsell, D.S. A semiempirical free energy force field with charge-based desolvation. J. Comput. Chem., 2007, 28(6), 1145-1152. doi: 10.1002/jcc.20634 PMID: 17274016Adasme, M.F.; Linnemann, K.L.; Bolz, S.N.; Kaiser, F.; Salentin, S.; Haupt, V.J.; Schroeder, M. PLIP 2021: Expanding the scope of the protein–ligand interaction profiler to DNA and RNA. Nucleic Acids Res., 2021, 49(W1), W530-W534. doi: 10.1093/nar/gkab294 PMID: 33950214Maier, J.A.; Martinez, C.; Kasavajhala, K.; Wickstrom, L.; Hauser, K.E.; Simmerling, C. ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB. J. Chem. Theory Comput., 2015, 11(8), 3696-3713. doi: 10.1021/acs.jctc.5b00255 PMID: 26574453Wang, J.; Wolf, R.M.; Caldwell, J.W.; Kollman, P.A.; Case, D.A. Development and testing of a general amber force field. J. Comput. Chem., 2004, 25(9), 1157-1174. doi: 10.1002/jcc.20035 PMID: 15116359Ryckaert, J.P.; Ciccotti, G.; Berendsen, H.J.C. Numerical integration of the cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes. J. Comput. Phys., 1977, 23(3), 327-341. doi: 10.1016/0021-9991(77)90098-5Berendsen, H.J.C.; Grigera, J.R.; Straatsma, T.P. The missing term in effective pair potentials. J. Phys. Chem., 1987, 91(24), 6269-6271. doi: 10.1021/j100308a038Sindhikara, D.J.; Kim, S.; Voter, A.F.; Roitberg, A.E. Bad seeds sprout perilous dynamics: Stochastic thermostat induced trajectory synchronization in biomolecules. J. Chem. Theory Comput., 2009, 5(6), 1624-1631. doi: 10.1021/ct800573m PMID: 26609854Petersen, H.G. Accuracy and efficiency of the particle mesh Ewald method. J. Chem. Phys., 1995, 103(9), 3668-3679. doi: 10.1063/1.470043Pastor, R.W.; Brooks, B.R.; Szabo, A. An analysis of the accuracy of Langevin and molecular dynamics algorithms. Mol. Phys., 1988, 65(6), 1409-1419. doi: 10.1080/00268978800101881Bouysset, C.; Fiorucci, S. ProLIF: A library to encode molecular interactions as fingerprints. J. Cheminform., 2021, 13(1), 72. doi: 10.1186/s13321-021-00548-6 PMID: 34563256Roe, D.R.; Cheatham, T.E., III PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. J. Chem. Theory Comput., 2013, 9(7), 3084-3095. doi: 10.1021/ct400341p PMID: 26583988Kollman, P.A.; Massova, I.; Reyes, C.; Kuhn, B.; Huo, S.; Chong, L.; Lee, M.; Lee, T.; Duan, Y.; Wang, W.; Donini, O.; Cieplak, P.; Srinivasan, J.; Case, D.A.; Cheatham, T.E., III Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models. Acc. Chem. Res., 2000, 33(12), 889-897. doi: 10.1021/ar000033j PMID: 11123888Weiser, J.; Shenkin, P.S.; Still, W.C. Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO). J. Comput. Chem., 1999, 20(2), 217-230. doi: 10.1002/(SICI)1096-987X(19990130)20:23.0.CO;2-ATian, W.; Li, D.; Zhang, N.; Bai, G.; Yuan, K.; Xiao, H.; Gao, F.; Chen, Y.; Wong, C.C.L.; Gao, G.F. O-glycosylation pattern of the SARS-CoV-2 spike protein reveals an "O-Follow-N" rule. Cell Res., 2021, 31(10), 1123-1125. doi: 10.1038/s41422-021-00545-2 PMID: 34341488Lopez, E.; Barthélémy, M.; Baronti, C.; Masse, S.; Falchi, A.; Durbesson, F.; Vincentelli, R.; de Lamballerie, X.; Charrel, R.; Coutard, B. Endonuclease-based genotyping of the RBM as a method to track the emergence or evolution of SARS-CoV-2 variants. iScience, 2021, 24(11), 103329. doi: 10.1016/j.isci.2021.103329 PMID: 34697603Bateman, A.; Martin, M-J.; Orchard, S.; Magrane, M.; Agivetova, R.; Ahmad, S.; Alpi, E.; Bowler-Barnett, E.H.; Britto, R.; Bursteinas, B.; Bye-A-Jee, H.; Coetzee, R.; Cukura, A.; Da Silva, A.; Denny, P.; Dogan, T.; Ebenezer, T.G.; Fan, J.; Castro, L.G.; Garmiri, P.; Georghiou, G.; Gonzales, L.; Hatton-Ellis, E.; Hussein, A.; Ignatchenko, A.; Insana, G.; Ishtiaq, R.; Jokinen, P.; Joshi, V.; Jyothi, D.; Lock, A.; Lopez, R.; Luciani, A.; Luo, J.; Lussi, Y.; MacDougall, A.; Madeira, F.; Mahmoudy, M.; Menchi, M.; Mishra, A.; Moulang, K.; Nightingale, A.; Oliveira, C.S.; Pundir, S.; Qi, G.; Raj, S.; Rice, D.; Lopez, M.R.; Saidi, R.; Sampson, J.; Sawford, T.; Speretta, E.; Turner, E.; Tyagi, N.; Vasudev, P.; Volynkin, V.; Warner, K.; Watkins, X.; Zaru, R.; Zellner, H.; Bridge, A.; Poux, S.; Redaschi, N.; Aimo, L.; Argoud-Puy, G.; Auchincloss, A.; Axelsen, K.; Bansal, P.; Baratin, D.; Blatter, M-C.; Bolleman, J.; Boutet, E.; Breuza, L.; Casals-Casas, C.; de Castro, E.; Echioukh, K.C.; Coudert, E.; Cuche, B.; Doche, M.; Dornevil, D.; Estreicher, A.; Famiglietti, M.L.; Feuermann, M.; Gasteiger, E.; Gehant, S.; Gerritsen, V.; Gos, A.; Gruaz-Gumowski, N.; Hinz, U.; Hulo, C.; Hyka-Nouspikel, N.; Jungo, F.; Keller, G.; Kerhornou, A.; Lara, V.; Le Mercier, P.; Lieberherr, D.; Lombardot, T.; Martin, X.; Masson, P.; Morgat, A.; Neto, T.B.; Paesano, S.; Pedruzzi, I.; Pilbout, S.; Pourcel, L.; Pozzato, M.; Pruess, M.; Rivoire, C.; Sigrist, C.; Sonesson, K.; Stutz, A.; Sundaram, S.; Tognolli, M.; Verbregue, L.; Wu, C.H.; Arighi, C.N.; Arminski, L.; Chen, C.; Chen, Y.; Garavelli, J.S.; Huang, H.; Laiho, K.; McGarvey, P.; Natale, D.A.; Ross, K.; Vinayaka, C.R.; Wang, Q.; Wang, Y.; Yeh, L-S.; Zhang, J.; Ruch, P.; Teodoro, D. UniProt: The universal protein knowledgebase in 2021. Nucleic Acids Res., 2021, 49(D1), D480-D489. doi: 10.1093/nar/gkaa1100 PMID: 33237286Tsueng, G.; Mullen, J.L.; Alkuzweny, M.; Cano, M.; Rush, B.; Haag, E.; Curators, O.; Latif, A.A.; Zhou, X.; Qian, Z.; Hufbauer, E.; Zeller, M.; Andersen, K.G.; Wu, C.; Su, A.I.; Gangavarapu, K.; Hughes, L.D. Outbreak.info research library: A standardized, searchable platform to discover and explore COVID-19 resources. bioRxiv, 2022, 2022, 477133. doi: 10.1101/2022.01.20.477133